Quotables
"There is practically no chance communications space satellites will be used to provide better telephone, telegraph, television, or radio service inside the United States."
T. Craven, FCC Commissioner ; 1961
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6592844 | Preparation of protein microspheres, films and coatings A process is described for preparing microspheres, films and coatings from protein or modified protein in which the protein product is stabilized by carrying out the preparation in the presence of an aqueous solution of at least one -hydroxy acid. ... | 07/15/2003 |
| 6514731 | Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens Human hepatitis C virus (HCV) has been identified as the aetiological agent of non-A, non-B hepatitis (NANBH). HCV viruses display considerable genotypic and phenotypic heterogeneity. Thus, there is considerable need in the art for more sensitive reagents... | 02/04/2003 |
| 6458370 | Use of microparticles combined with submicron oil-in-water emulsions Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject ... | 10/01/2002 |
| 6451325 | Adjuvant formulation comprising a submicron oil droplet emulsion An adjuvant composition, comprising a metabolizable oil and an emulsifying agent, wherein the oil and the detergent are present in the form of an oil-in-water emulsion having oil droplets substantially all of which are less than 1 micron in diameter. In p... | 09/17/2002 |
| 6416944 | Methods of typing hepatitis C virus and reagents for use therein The claimed invention provides methods of detecting and typing HCV using nucleic acid molecules encoding type specific and type-cluster specific epitopes. The nucleic acid molecules flanking regions encoding type specific or type cluster specific epitopes... | 07/09/2002 |
| 6416946 | Methods of typing hepatitis C virus and reagents for use therein The present invention provides methods and compositions for use therein for typing hepatitis C viruses.... | 07/09/2002 |
| 6413520 | Methods of immunizing adults using anti-meningococcal vaccine compositions A method for boosting an immune response against meningococcal capsular antigen is disclosed. The method entails administering a first glycoconjugate vaccine composition to a subject to provide an initial state of anti-meningococcal immunity, and then boo... | 07/02/2002 |
| 6355247 | Nucleic acid immunization using a virus-based infection/transfection system A method for nucleic acid immunization which results in a cell-mediated immunological response to a selected antigen is disclosed. The method utilizes the T7 RNA infection/transfection system which provides for the controlled, transient cytoplasmic expres... | 03/12/2002 |
| 6326171 | Hepatitis C E1 and E2 truncated polypeptides and methods of obtaining the same Novel Hepatitis C E1 and E2 truncated polypeptides and complexes comprising these polypeptides, are disclosed. The polypeptides are C-terminally truncated to remove all or a portion of their membrane spanning domains. Hence, the polypeptides are capable o... | 12/04/2001 |
| 6306405 | Use of microparticles combined with submicron oil-in-water emulsions Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject ... | 10/23/2001 |
| 6300102 | Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa oute... | 10/09/2001 |
| 6274148 | Hepatitis C virus asialoglycoproteins Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which ar... | 08/14/2001 |
| 6121020 | Hepatitis C E1 and E2 polypeptides and methods of obtaining the same Novel Hepatitis C E1 and E2 truncated polypeptides and complexes comprising these polypeptides, are disclosed. The polypeptides are C-terminally truncated to remove all or a portion of their membrane spanning domains. Hence, the polypeptides are capable o... | 09/19/2000 |
| 6096505 | Noncloning technique for expressing a gene of interest A noncloning method for expressing a gene of interest in a mammalian host cell is disclosed. The invention utilizes three basic individual elements: (1) a promoter element; (2) at least one gene of interest; and (3) a selectable marker cassette which incl... | 08/01/2000 |
| 6074852 | Hepatitis C virus asialoglycoproteins Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which ar... | 06/13/2000 |
| 6060068 | Human IL-2 as a vaccine adjuvant Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing th... | 05/09/2000 |
| 6054264 | Methods of typing hepatitis C virus and reagents for use therein The claimed invention provides methods of detecting and typing HCV using type specific and type-cluster specific epitopes. The claimed invention also provides peptides having type specific and type-cluster specific epitopes.... | 04/25/2000 |
| 6048527 | Antibodies that define unique Meningococcal B epitopes and vaccine compositions Novel bactericidal antibodies against Neisseria meningitidis serogroup B ("MenB") are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The ant... | 04/11/2000 |
| 6030619 | Molecular mimetics of meningococcal B epitopes Molecular mimetics of unique epitopes of Neisseria meningitidis serogroup B ("MenB") are disclosed. Compositions containing such molecular mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody responses.... | 02/29/2000 |
| 6007791 | Preparation of protein microspheres, films and coatings A process is described for preparing microspheres, films and coatings from protein or modified protein in which the protein product is stabilized by carrying out the preparation in the presence of an aqueous solution of at least one -hydroxy acid. ... | 12/28/1999 |
| 5965140 | Hybrid particle immunogens Novel immunogenic compositions are provided involving viral particles composed at least in part of hybrid proteins of at least a portion of a particle forming protein and one or more polypeptides having at least one epitope of interest. Nucleic acid seque... | 10/12/1999 |
| 5834307 | Polynucleotides encoding CMV neutralizing proteins The present invention provides recombinant polypeptides derived from CMV glycoprotein gB and truncated fragments thereof which contain at least one epitope which is immunologically identifiable with one encoded by the CMV genome. The complete characteriza... | 11/10/1998 |
| 5792463 | Hybrid particle immunogens Novel immunogenic compositions are provided involving viral particles composed at least in part of hybrid proteins of at least a portion of a particle forming protein and one or more polypeptides having at least one epitope of interest. Nucleic acid seque... | 08/11/1998 |
